Comparison of antitumor efficacy of first-line palbociclib, ribociclib, or abemaciclib in patients with HR+/HER2- aBC: Results of the multicenter, real-world, Italian study PALMARES-2.
Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Donata Sartori(Ospedale di Mirano), Giuseppe Curigliano(European Institute of Oncology), Angela Toss(University of Modena and Reggio Emilia), Daniele Generali(University of Trieste), Alberto Zambelli, Monica Giordano(Ospedale Sant'Anna), Andrea Botticelli(Sapienza University of Rome), Nicla La Verde(ASST Fatebenefratelli Sacco), Daniela Miliziano(Fondazione IRCCS Istituto Nazionale dei Tumori), Alessandra Gennari(Ente Ospedaliero Ospedali Galliera), Mario Giuliano(Regione Campania), Marianna Sirico(Istituti Ospitalieri di Cremona), Barbara Tagliaferri(Istituti Clinici Scientifici Maugeri), Maria Vittoria Dieci(Istituto Oncologico Veneto), Matteo Lambertini(Ospedale Policlinico San Martino), Rebecca Pedersini(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Leonardo Provenzano(Fondazione IRCCS Istituto Nazionale dei Tumori), Gianpiero Rizzo(Policlinico San Matteo Fondazione), Marta Piras(Vita-Salute San Raffaele University)
Cited by 7
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k